上海臨港(600848.SH):擬出資1.5億元認購申創產城基金
格隆匯8月11日丨上海臨港(600848.SH)公佈,公司全資子公司上海臨港經濟發展集團投資管理有限公司(“臨港投資”)擬作為有限合夥人(LP)出資人民幣1.5億元,認購上海申創產城私募基金合夥企業(有限合夥)(暫定名,最終以工商註冊確定的名稱為準,“申創產城基金”)認繳出資總額的3.8820%。
申創產城基金投資於科技創新、傳統產業轉型升級、戰略新興產業發展、國資國企改革等行業和領域,該基金尚處於籌劃設立階段,尚未完成工商註冊登記,尚需取得中國證券投資基金業協會備案。目前,基金的合夥協議尚未簽署,合同內容和具體操作方式以最終各方簽署的正式合同文本為準,實施過程存在一定不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.